Navigation Links
Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine
Date:10/21/2011

H1N1 (A/California/07/2009) and H3N2 (A/Victoria/210/2009) strains. 

Safety was monitored for 21 days after vaccination. Blood specimens for immunogenicity (hemagglutination inhibition [HI assay]) were collected pre- and 21 days post-vaccination.

Immunogenicity and Safety Data In this investigational study, the immune responses to QIV were non-inferior to both of the control TIVs with respect to all four strains contained in the vaccine as measured by GMTs. For seroconversion rates, immune responses to QIV were non-inferior to those of the control TIVs with respect to all strains, except A/H1N1. 

Superiority was assessed by comparing antibody responses to each B strain in QIV with those induced by the TIV that did not contain the corresponding B strain.  For GMTs, superiority was demonstrated for the B/Florida (B2) strain in QIV, but not for B/Brisbane (B1). Although superiority of GMT for B/Brisbane was not achieved, the GMT was numerically superior and statistically non-inferior in QIV compared with the investigational TIV. 

For all groups in this investigational study, the most frequently reported solicited injection-site reaction was pain. The most frequently reported solicited systemic reactions were myalgia, headache and malaise. Three serious adverse events were reported in the study, but did not occur among QIV recipients and were not considered related to the study vaccine.

About Sanofi Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vacci
'/>"/>

SOURCE Sanofi Pasteur
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
2. Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
3. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
4. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
5. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
6. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
7. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
8. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
9. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
10. Sanofi-aventis Stands Behind the Safety of Lantus(R)
11. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... The global Bioinformatics ... sectors, products & services and application. And the rising ... increasing demand of advanced drugs for the diagnosis ... growth for bioinformatics market. The implementation of information ... as bioinformatics. Decreasing cost of DNA sequencing, continuous ...
(Date:9/1/2015)... Research and Markets ( http://www.researchandmarkets.com/research/r8v22b/regulatory ) has announced the ... (London, UK - September 24-25, 2015)" conference to ... provides an introduction to Pharmaceutical Regulatory Affairs and the ... for those working in a support staff role. ... regulatory procedures required to register products in ...
(Date:9/1/2015)... , September 1, 2015 - ... GARFIELD-AF R egistry data presented at ... on the evolution of manag ... -   The first-ever two-year outcomes from ... ESC Congress 2015 expose that all-cause death was the most frequent major event ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9
(Date:9/1/2015)... ... September 01, 2015 , ... ... a top-five hospital by U.S. News & World Report, to provide breaking news ... , Editorial and marketing groups within OncLive, which provides oncologists resources and information?they ...
(Date:9/1/2015)... ... September 01, 2015 , ... The Jerry Segal Classic to benefit ... and Green Valley Country Club in Lafayette Hill, PA. Over the past 26 years, ... million for programs and services designed to support patients and their families during their ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... With former ... Engineering and Math) disciplines since its inception more than 35 years ago. A pilot ... students and their teachers - and, not just those intent on pursuing careers in ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... the release of version 5.2 of the FirstSpirit Content Management System with new ... With the new version of FirstSpirit, companies will be well on their way ...
(Date:9/1/2015)... ... September 01, 2015 , ... Zecurion, a leading developer of data loss prevention ... of endpoint DLP developed specifically for Mac OS. , In June 2015, the company ... and information security professionals had participated. The beta test done by the developer community ...
Breaking Medicine News(10 mins):Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:Zecurion Announces Endpoint Security for Mac 2
... recent increase in the number of men who are going under ... of men undergoing nip and tuck surgery has rocketed by 140 ... ,The phenomenon has been dubbed the 'menopaunch' as men fork ... to be facing pressures as women to look good thus they ...
... and body, a rare medical anomaly. And doctors say that laser ... ,Prithviraj Patil, son of a well-to-do farmer in Sangalwadi near ... like any normal child. ,,Prithiviraj has no problem with his ... awful - there is no itch or rash on the skin ...
... A type of skin cancer that was rare three decades ... the Journal of the American Medical Association (JAMA) found . ... increasingly more common in the United States in the decades ... July issue of Archives of Dermatology, which is part of ...
... on a teenager from wearing a so-called "purity ring" at school ... ,Lydia Playfoot, 16, said she was "disappointed" by the ruling in ... West Sussex, denies infringing her human rights, saying that the ring ... its uniform policy. ,"As a Christian I do not ...
... could dramatically lower the rapidly rising costs of several ... specialists suggest in a commentary in the Journal ... Mark Ratain, MD, and Ezra Cohen, MD, call attention ... certain foods can alter absorption or delay breakdown of ...
... is a universal problem that doctors need to ... Wake Forest University School of Medicine in ... Archives of Dermatology. ,He said non-compliance ... to treatment. ,Physicians must develop practical ...
Cached Medicine News:Health News:Men Under Knife to Reduce Bulging Waistline in Britian 2Health News:Hairy Boy Bets on Laser Treatment for Cure 2Health News:Value Meal Would Lower Drug Costs 2Health News:Value Meal Would Lower Drug Costs 3Health News:Patients Not Complying With Their Dermatologic Problem 2Health News:Patients Not Complying With Their Dermatologic Problem 3
Used to negotiate tortuous vessels....
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary Stent ... drug, called "sirolimus", a controlled-release ... delivery platform. Upon placement, sirolimus ... and impedes the process of ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Medicine Products: